查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2035378

2034年醫藥中間體市場預測－按產品類型、合成流程、治療應用、最終使用者和地區分類的全球分析

Pharmaceuticals Intermediates Market Forecasts to 2034 - Global Analysis By Product Type, Synthesis Process, Therapeutic Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球醫藥中間體市場規模將達到 487 億美元，並在預測期內以 7.1% 的複合年成長率成長，到 2034 年將達到 842 億美元。

醫藥中間體是合成活性藥物成分（API）的關鍵前體，是重要的化學物質。它們透過複雜的多步驟化學反應生產，對最終藥物的品質、安全性和療效有顯著影響。這些化合物廣泛用於生產抗生素、抗病毒藥物、止痛藥和心血管藥物。醫藥產業的擴張、疾病發生率的上升以及藥物研發活動的活性化，都推動了對這些中間體需求的成長。此外，日益嚴格的監管要求和化學製造技術的不斷改進，也推動了全球醫藥中間體產業的標準、創新和效率的提升。

根據印度藥品醫療器材管理局 2023-24 年度報告，2023 年印度藥品出口額達到 254 億美元，其中中間體和原料藥佔大部分。

慢性病盛行率上升

醫藥中間體市場的成長主要受癌症、糖尿病、心臟病和呼吸系統疾病等慢性病負擔日益加重的驅動。這些疾病需要持續治療，進而增加了對原料藥及其中間體的需求。人口老化和不健康的生活方式進一步加劇了全球疾病的發生。隨著醫療保健和醫療基礎設施的改善，藥品產量正在快速成長。對有效治療方案的持續需求確保了全球醫藥產業中間體的持續成長，並顯著增強了整體長期市場擴張趨勢。

高昂的製造成本和營運成本

由於生產和營運成本高昂，醫藥中間體市場面臨許多限制。生產中間體需要昂貴的原料、專門的化學製程以及大量的能源消耗。此外，企業還需要完善的生產基礎設施和熟練的專業人員來確保符合監管要求和產品品質。不斷上漲的公用事業、物流和供應鏈營運成本進一步加劇了企業的財務壓力。這些高成本降低了盈利，使得小規模製造商難以在競爭激烈的市場中生存。因此，進入門檻依然很高，企業在努力維持成本效益的同時，還要滿足嚴格的全球醫藥生產標準，導致整個產業的成長速度放緩。

綠色化學技術的進步

綠色化學的進步透過推廣環境友善生產技術，為醫藥中間體產業創造了強勁的成長潛力。製造商正轉向能夠最大限度減少污染、減少廢棄物並最佳化資源利用的方法。生物催化和更清潔的反應路徑等技術正在提高效率並降低對環境的影響。這些永續的方法也有助於企業遵守嚴格的環境法規並降低營運成本。全球對永續性的日益重視正在推動綠色工藝的更廣泛應用。因此，綠色化學正成為全球醫藥中間體產業創新和長期競爭力的關鍵驅動力。

嚴格施壓以遵守法規

醫藥中間體市場受到嚴格監管要求的嚴重影響，這些要求構成重大威脅。企業必須遵守全球監管機構制定的詳盡的安全、品質和環境保護準則。要達到這些標準需要大量的文件記錄、測試和持續監控，這增加了營運難度。違反監管規定可能導致罰款、產品召回，甚至銷售禁令。頻繁的監管變化進一步加劇了不確定性，並推高了合規成本。中小製造商尤其受到影響，因為它們往往缺乏足夠的資源來有效應對這些要求。所有這些監管壓力都在削弱全球醫藥中間體產業的柔軟性，並減緩其成長。

新型冠狀病毒（COVID-19）的影響：

新冠疫情為醫藥中間體產業帶來了挑戰和機會。疫情初期，包括封鎖和勞動力短缺在內的各種限制措施嚴重擾亂了物流、原料供應和生產活動。許多製造地不得不降低運轉率，導致生產延誤。然而，全球醫療保健需求的激增增加了對藥品的需求，間接推動了基本藥物中間體的消費。這也促使各國政府和企業加強國內生產，並加強研發投入，提升供應鏈韌性。最終，儘管新冠疫情暴露了產業結構性脆弱性，但也促進了全球醫藥中間體產業的長期擴張和策略轉型。

在預測期內，原料藥成分中間體細分市場預計將佔據最大的市場佔有率。

由於活性原料藥成分（API）中間體廣泛應用於活性藥物成分的大規模生產，預計在預測期內，API中間體市場將佔據最大的市場佔有率。這些化合物是多種藥物（包括止痛藥、抗生素和心血管藥物）生產的基礎成分。它們適合大規模生產以及製藥廠商的穩定需求，鞏固了其主導地位。不斷成長的醫療保健需求和日益擴大的製藥生產活動持續提升其重要性，使其成為全球中間體產業中最重要、應用最廣泛的細分市場。

在預測期內，腫瘤（癌症治療）領域預計將呈現最高的複合年成長率。

在預測期內，受全球癌症發生率上升的推動，腫瘤（癌症治療）領域預計將呈現最高的成長率。人口老化、環境因素和生活方式的改變導致病例增加，從而推動了對有效癌症療法的需求。由於合成途徑的複雜性，腫瘤藥物的研發需要高度專業化的中間體。精準醫療、免疫療法和標靶藥物療法的進步正在推動該領域的進一步快速成長。製藥公司對癌症研究和創新治療方案的大量投資也強化了這一趨勢。因此，腫瘤領域仍是全球中間體產業成長最快的領域。

市佔率最大的地區：

在預測期內，亞太地區憑藉其龐大的生產能力和成本優勢，預計將佔據最大的市場佔有率。該地區，尤其是中國和印度，是醫藥活性成分和中間體的主要生產中心。完善的化學基礎設施、價格合理的原料供應以及豐富的熟練勞動力，都為該地區的主導地位提供了支撐。政府的各項措施和出口導向政策支持醫藥產業的成長，進一步增強了市場的實力。憑藉著良好的營商環境和大規模的產業發展，亞太地區將繼續成為全球醫藥中間體產業最具影響力的地區。

複合年成長率最高的地區：

在預測期內，北美預計將呈現最高的複合年成長率，這主要得益於醫藥創新和研發活動的強勁成長。該地區匯聚了許多領先的製藥和生物技術公司，它們正積極研發針對複雜疾病的先進治療方法。對新型治療方法（尤其是癌症和罕見疾病療法）日益成長的需求，顯著推動了中間產品的消費。完善的醫療保健體系、先進的生產技術以及充足的研發資金支持，進一步促進了市場成長。此外，嚴格的品質要求也推動了技術的持續創新。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球醫藥中間體市場：依產品類型分類

  • 原料藥中間體
  • 承包和中介
  • 特殊化學中間體

第6章 全球醫藥中間體市場：依合成流程分類

  • 傳統間歇式化學
  • 連續流動化學
  • 生物催化和酵素合成

第7章 全球醫藥中間體市場：依治療應用分類

  • 腫瘤學
  • 抗感染藥物和抗菌藥物
  • 止痛藥
  • 糖尿病藥物
  • 循環系統藥物
  • 抗發炎藥
  • 其他治療用途

第8章 全球醫藥中間體市場：依最終用戶分類

  • 學名藥生產商
  • 生物製藥公司
  • 契約製造公司（CMO）
  • 受託研究機構（CRO）
  • 其他最終用戶

第9章 全球醫藥中間體市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • Chiracon GmbH
  • BASF SE
  • Sanofi SA
  • Aceto Corporation
  • Codexis, Inc.
  • Aarti Industries Limited
  • Curia Global, Inc.
  • Dishman Carbogen Amcis Ltd.
  • Jubilant Pharmova Limited
  • Merck KGaA
  • Hetero Labs Limited
  • Pfizer Inc.
  • Asymchem Laboratories
  • Porton Pharma Solutions Ltd.
  • Almac Group Ltd.
  • Laxmi Organic Industries Ltd.
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
Product Code: SMRC35440

According to Stratistics MRC, the Global Pharmaceuticals Intermediates Market is accounted for $48.7 billion in 2026 and is expected to reach $84.2 billion by 2034 growing at a CAGR of 7.1% during the forecast period. Pharmaceutical intermediates are vital chemical substances used as key precursors in the synthesis of active pharmaceutical ingredients (APIs). They are produced through complex multi-stage chemical reactions and significantly influence the quality safety and effectiveness of finished medicines These compounds are extensively applied in the production of antibiotics antiviral pain relievers and heart-related drugs Growing demand for these intermediates is driven by the expanding pharmaceutical sector increasing incidence of diseases and rising research activities in drug development Additionally strict regulatory requirements and continuous improvements in chemical manufacturing techniques are encouraging higher standards innovation and efficiency in the intermediates industry globally widely

According to the Department of Pharmaceuticals Annual Report 2023-24, India's pharmaceutical exports reached USD 25.4 billion in FY 2023, with intermediates and APIs forming a substantial share.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

Pharmaceutical intermediates market growth is largely supported by the rising burden of chronic illnesses including cancer diabetes heart diseases and respiratory conditions. These diseases require ongoing treatments which increases the need for APIs and their intermediate compounds. Growing elderly populations and unhealthy lifestyle patterns are further accelerating disease cases worldwide. With improving healthcare access and expanding medical infrastructure pharmaceutical production is increasing rapidly. The consistent requirement for effective therapeutic solutions ensures sustained growth of intermediates across global pharmaceutical industries and strengthens long-term market expansion trends significantly overall.

Restraint:

High production and operational costs

The pharmaceutical intermediates market faces limitations due to high manufacturing and operational expenses. Producing intermediates requires costly raw materials, specialized chemical processes, and significant energy consumption. Companies also need advanced production infrastructure and trained professionals to ensure regulatory compliance and product quality. Increasing costs of utilities, logistics, and supply chain operations add further financial pressure. These high expenses reduce profitability and make it difficult for smaller manufacturers to survive in competitive markets. Consequently, entry barriers remain high, and overall industry growth is slowed as companies struggle to maintain cost efficiency while meeting strict pharmaceutical production standards worldwide.

Opportunity:

Advancements in green chemistry technologies

Green chemistry advancements offer strong growth potential in the pharmaceutical intermediates sector by promoting eco-friendly production techniques. Manufacturers are shifting toward methods that minimize pollution reduce waste and optimize resource utilization. Technologies like biocatalysis and cleaner reaction pathways are enhancing efficiency and lowering environmental impact. These sustainable approaches also help companies comply with strict environmental regulations and reduce operational costs. Increasing global emphasis on sustainability is encouraging wider adoption of green processes. As a result green chemistry is becoming a key driver of innovation and long-term competitiveness in the pharmaceutical intermediates industry across global markets.

Threat:

Stringent regulatory compliance pressure

The pharmaceutical intermediates market is heavily impacted by strict regulatory obligations, which act as a significant threat. Companies must follow detailed guidelines related to safety quality and environmental protection imposed by global regulatory agencies. Meeting these standards requires extensive documentation testing and ongoing monitoring, which increases operational difficulty. Failure to comply can lead to fines product recalls or even bans. Frequent regulatory changes add further uncertainty and raise compliance costs. Smaller manufacturers are particularly affected as they lack sufficient resources to manage these requirements effectively. Overall regulatory pressure reduces flexibility and slows down growth in the intermediates industry worldwide.

Covid-19 Impact:

The COVID-19 outbreak created both challenges and opportunities for the pharmaceutical intermediates industry. Early pandemic restrictions caused severe disruptions in logistics, raw material supply, and production activities due to lockdowns and workforce limitations. Many manufacturing units operated at reduced capacity, delaying output. However, the surge in global healthcare demand increased the need for medicines, indirectly boosting intermediate consumption for essential drugs. It also encouraged governments and companies to strengthen domestic production and invest in research and supply chain resilience. Ultimately, COVID-19 exposed structural weaknesses but also supported long-term expansion and strategic transformation in the pharmaceutical intermediates sector worldwide.

The bulk drug intermediates segment is expected to be the largest during the forecast period

The bulk drug intermediates segment is expected to account for the largest market share during the forecast period as they are widely used in the mass production of active pharmaceutical ingredients. These compounds serve as fundamental components in the creation of various medicines such as pain reliever's antibiotics and heart-related drugs. Their suitability for large-scale manufacturing and consistent demand from drug producers support their leading position. Growing healthcare needs and rising pharmaceutical production activities continue to reinforce their importance, making them the most significant and widely utilized segment in the global intermediates industry.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate, driven by the rising prevalence of cancer worldwide. Increasing cases linked to aging populations, environmental factors, and lifestyle changes are boosting demand for effective cancer treatments. Drug development in oncology requires highly specialized intermediates due to complex synthesis pathways. Advances in precision medicine, immunotherapy, and targeted drug therapies are further supporting rapid expansion. Significant investments by pharmaceutical companies in cancer research and innovative treatment solutions are strengthening this trend. As a result, oncology remains the fastest expanding segment within the global intermediates industry.

Region with largest share:

During the forecast period, the Asia-Pacific region is expected to hold the largest market share owing to its extensive production capabilities and cost advantages. The region, especially China and India, serves as a key center for manufacturing active pharmaceutical ingredients and intermediates. Strong chemical infrastructure, availability of affordable raw materials, and abundant skilled workforce contribute to its leadership position. Government initiatives supporting pharmaceutical growth and export-oriented policies further enhance market strength. Combined with favourable business conditions and large-scale industrial development, Asia-Pacific continues to remain the most influential region in the global intermediates industry.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, supported by strong expansion in drug innovation and R&D activities. The region is home to major pharmaceutical and biotech companies that are actively developing advanced therapies for complex diseases. Increasing demand for novel treatments, particularly in cancer and rare conditions, is significantly driving intermediate consumption. Well-developed healthcare systems, advanced production technologies, and supportive research funding further strengthen market growth. In addition, strict quality requirements encourage continuous technological improvement.

Key players in the market

Some of the key players in Pharmaceuticals Intermediates Market include Chiracon GmbH, BASF SE, Sanofi S.A., Aceto Corporation, Codexis, Inc., Aarti Industries Limited, Curia Global, Inc., Dishman Carbogen Amcis Ltd., Jubilant Pharmova Limited, Merck KGaA, Hetero Labs Limited, Pfizer Inc., Asymchem Laboratories, Porton Pharma Solutions Ltd., Almac Group Ltd., Laxmi Organic Industries Ltd., Lonza Group AG and Thermo Fisher Scientific Inc.

Key Developments:

In November 2025, Merck KGaA has signed a 20-year power purchase agreement (PPA) with SK Innovation E&S to supply renewable electricity to its life science manufacturing sites in Daejeon and Songdo, South Korea. The agreement adds 16 megawatts (MW) of new renewable capacity and represents the company's longest energy commitment in the Asia-Pacific region.

In October 2025, BASF SE and ANDRITZ Group have signed a license agreement for the use of BASF's proprietary gas treatment technology, OASE(R) blue, in a carbon capture project planned to be implemented in the city of Aarhus, Denmark. The project aims to capture approximately 435,000 tons of CO2 annually from the flue gases of a waste-to-energy plant for sequestration; the city of Aarhus has set itself the goal of becoming CO2-neutral by 2030.

In October 2025, Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials. The deal includes potential additional earnout and other payments contingent on future performance. Clario's platform integrates clinical trial endpoint data from devices, sites, and patients, enabling pharmaceutical and biotechnology companies to digitally collect, manage, and analyze clinical evidence across all phases of drug development.

Product Types Covered:

  • Bulk Drug Intermediates
  • Custom & Contract Intermediates
  • Specialty Chemical Intermediates

Synthesis Processes Covered:

  • Traditional Batch Chemistry
  • Continuous Flow Chemistry
  • Biocatalysis & Enzymatic Synthesis

Therapeutic Applications Covered:

  • Oncology
  • Anti-Infective & Antimicrobial Drugs
  • Analgesics
  • Antidiabetic Drugs
  • Cardiovascular Drugs
  • Anti-Inflammatory Drugs
  • Other Therapeutic Applications

End Users Covered:

  • Generic Drug Manufacturers
  • Biopharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pharmaceuticals Intermediates Market, By Product Type

  • 5.1 Bulk Drug Intermediates
  • 5.2 Custom & Contract Intermediates
  • 5.3 Specialty Chemical Intermediates

6 Global Pharmaceuticals Intermediates Market, By Synthesis Process

  • 6.1 Traditional Batch Chemistry
  • 6.2 Continuous Flow Chemistry
  • 6.3 Biocatalysis & Enzymatic Synthesis

7 Global Pharmaceuticals Intermediates Market, By Therapeutic Application

  • 7.1 Oncology
  • 7.2 Anti-Infective & Antimicrobial Drugs
  • 7.3 Analgesics
  • 7.4 Antidiabetic Drugs
  • 7.5 Cardiovascular Drugs
  • 7.6 Anti-Inflammatory Drugs
  • 7.7 Other Therapeutic Applications

8 Global Pharmaceuticals Intermediates Market, By End User

  • 8.1 Generic Drug Manufacturers
  • 8.2 Biopharmaceutical Companies
  • 8.3 Contract Manufacturing Organizations (CMOs)
  • 8.4 Contract Research Organizations (CROs)
  • 8.5 Other End Users

9 Global Pharmaceuticals Intermediates Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 Chiracon GmbH
  • 12.2 BASF SE
  • 12.3 Sanofi S.A.
  • 12.4 Aceto Corporation
  • 12.5 Codexis, Inc.
  • 12.6 Aarti Industries Limited
  • 12.7 Curia Global, Inc.
  • 12.8 Dishman Carbogen Amcis Ltd.
  • 12.9 Jubilant Pharmova Limited
  • 12.10 Merck KGaA
  • 12.11 Hetero Labs Limited
  • 12.12 Pfizer Inc.
  • 12.13 Asymchem Laboratories
  • 12.14 Porton Pharma Solutions Ltd.
  • 12.15 Almac Group Ltd.
  • 12.16 Laxmi Organic Industries Ltd.
  • 12.17 Lonza Group AG
  • 12.18 Thermo Fisher Scientific Inc.

List of Tables

  • Table 1 Global Pharmaceuticals Intermediates Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pharmaceuticals Intermediates Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Pharmaceuticals Intermediates Market Outlook, By Bulk Drug Intermediates (2023-2034) ($MN)
  • Table 4 Global Pharmaceuticals Intermediates Market Outlook, By Custom & Contract Intermediates (2023-2034) ($MN)
  • Table 5 Global Pharmaceuticals Intermediates Market Outlook, By Specialty Chemical Intermediates (2023-2034) ($MN)
  • Table 6 Global Pharmaceuticals Intermediates Market Outlook, By Synthesis Process (2023-2034) ($MN)
  • Table 7 Global Pharmaceuticals Intermediates Market Outlook, By Traditional Batch Chemistry (2023-2034) ($MN)
  • Table 8 Global Pharmaceuticals Intermediates Market Outlook, By Continuous Flow Chemistry (2023-2034) ($MN)
  • Table 9 Global Pharmaceuticals Intermediates Market Outlook, By Biocatalysis & Enzymatic Synthesis (2023-2034) ($MN)
  • Table 10 Global Pharmaceuticals Intermediates Market Outlook, By Therapeutic Application (2023-2034) ($MN)
  • Table 11 Global Pharmaceuticals Intermediates Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 12 Global Pharmaceuticals Intermediates Market Outlook, By Anti-Infective & Antimicrobial Drugs (2023-2034) ($MN)
  • Table 13 Global Pharmaceuticals Intermediates Market Outlook, By Analgesics (2023-2034) ($MN)
  • Table 14 Global Pharmaceuticals Intermediates Market Outlook, By Antidiabetic Drugs (2023-2034) ($MN)
  • Table 15 Global Pharmaceuticals Intermediates Market Outlook, By Cardiovascular Drugs (2023-2034) ($MN)
  • Table 16 Global Pharmaceuticals Intermediates Market Outlook, By Anti-Inflammatory Drugs (2023-2034) ($MN)
  • Table 17 Global Pharmaceuticals Intermediates Market Outlook, By Other Therapeutic Applications (2023-2034) ($MN)
  • Table 18 Global Pharmaceuticals Intermediates Market Outlook, By End User (2023-2034) ($MN)
  • Table 19 Global Pharmaceuticals Intermediates Market Outlook, By Generic Drug Manufacturers (2023-2034) ($MN)
  • Table 20 Global Pharmaceuticals Intermediates Market Outlook, By Biopharmaceutical Companies (2023-2034) ($MN)
  • Table 21 Global Pharmaceuticals Intermediates Market Outlook, By Contract Manufacturing Organizations (CMOs) (2023-2034) ($MN)
  • Table 22 Global Pharmaceuticals Intermediates Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 23 Global Pharmaceuticals Intermediates Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.